CN109593089A - 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 - Google Patents
二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 Download PDFInfo
- Publication number
- CN109593089A CN109593089A CN201910070042.5A CN201910070042A CN109593089A CN 109593089 A CN109593089 A CN 109593089A CN 201910070042 A CN201910070042 A CN 201910070042A CN 109593089 A CN109593089 A CN 109593089A
- Authority
- CN
- China
- Prior art keywords
- compound
- diazaspiro
- piperidine
- oxo
- decane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- -1 formyl amine compound Chemical class 0.000 title claims description 22
- YMANQWHUUFJQOW-UHFFFAOYSA-N 1,2-diazaspiro[4.5]decane Chemical compound N1NCCC11CCCCC1 YMANQWHUUFJQOW-UHFFFAOYSA-N 0.000 title description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 11
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 229920002101 Chitin Polymers 0.000 claims abstract description 8
- 241000233866 Fungi Species 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 241000222122 Candida albicans Species 0.000 claims description 7
- 229940095731 candida albicans Drugs 0.000 claims description 7
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 5
- 229940091771 aspergillus fumigatus Drugs 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 claims description 4
- 201000007336 Cryptococcosis Diseases 0.000 claims description 4
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 229940125782 compound 2 Drugs 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 4
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 241000228197 Aspergillus flavus Species 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 2
- 229960003085 meticillin Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 150000003413 spiro compounds Chemical class 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims description 2
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims 1
- 230000001775 anti-pathogenic effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- KVCKVBITXIPQHE-UHFFFAOYSA-N N1(CCCCC1)C(=O)N.O=C1NCCC12CCNCC2 Chemical class N1(CCCCC1)C(=O)N.O=C1NCCC12CCNCC2 KVCKVBITXIPQHE-UHFFFAOYSA-N 0.000 abstract description 3
- 241000192125 Firmicutes Species 0.000 abstract description 2
- 239000001257 hydrogen Substances 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 150000004982 aromatic amines Chemical class 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000001408 fungistatic effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 44
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 44
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 33
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 239000000843 powder Substances 0.000 description 20
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
- 150000003053 piperidines Chemical class 0.000 description 13
- 239000000243 solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 3
- 229960004884 fluconazole Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QMKBNQSBQGDFHU-UHFFFAOYSA-N 5-bromo-3-[[2-(4-cyclohexyl-1-piperazinyl)-1-oxoethyl]amino]-1H-indole-2-carboxylic acid methyl ester Chemical compound COC(=O)C=1NC2=CC=C(Br)C=C2C=1NC(=O)CN(CC1)CCN1C1CCCCC1 QMKBNQSBQGDFHU-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229930182764 Polyoxin Natural products 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- YEBIHIICWDDQOL-YBHNRIQQSA-N polyoxin Polymers O[C@@H]1[C@H](O)[C@@H](C(C=O)N)O[C@H]1N1C(=O)NC(=O)C(C(O)=O)=C1 YEBIHIICWDDQOL-YBHNRIQQSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MFYLRNKOXORIPK-UHFFFAOYSA-N (3-nitrophenyl)-phenylmethanone Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 MFYLRNKOXORIPK-UHFFFAOYSA-N 0.000 description 1
- UEMGWPRHOOEKTA-UHFFFAOYSA-N 1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1 UEMGWPRHOOEKTA-UHFFFAOYSA-N 0.000 description 1
- ZJDWMGREEOZXTH-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperidine Chemical class COC1=CC=CC=C1N1CCCCC1 ZJDWMGREEOZXTH-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- PJFDLETUJCTQCK-UHFFFAOYSA-N CCCCCCCCCC.N1CCCCC1 Chemical class CCCCCCCCCC.N1CCCCC1 PJFDLETUJCTQCK-UHFFFAOYSA-N 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Substances [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 1
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 1
- 108010029768 Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000005059 solid analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了1‑氧代‑2,8‑二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物及其制备方法和应用，所述化合物的结构如通式1所示：式中R1为氢；R2为：各类取代的芳胺。经生物活性测试实验证明，部分化合物对革兰阳性菌、革兰阴性菌和真菌都有一定抑制活性，而且对几丁质合成酶抑制活性明显，抑菌效果较好，可用于制备抗病原微生物的药物。并且制备原料简单，廉价易得，对抗感染方面的应用具有重要意义。
Description
技术领域
本发明属医药领域，具体涉及1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物的设计合成及其在抗微生物方面的应用。
背景技术
近些年，随着国内外医疗水平的快速发展，许多顽固疾病得到了有效的治疗，但由于抗生素的滥用、肿瘤放化疗、器官移植抗排斥和艾滋病等原因造成机体免疫力低下，使得由白色念珠菌、烟曲霉菌、新型隐球菌等常见真菌引起的真菌感染发病率与死亡率逐年上升，已严重威胁人类的健康。因此，探索与合成一种新型抗菌类药物已成为国内外医学领域学者的研究热点。
螺环结构是天然产物与药物化合物中常见的一种环状化合物，因其自身具备的独特结构及其特殊性质被广泛应用于医学、农药、不对称催化等各领域，且具有螺环结构的化合物生物活性均要高于非螺环化合物。研究发现，具有酰胺基团的分子在在抗癌、抗病毒、抗菌、消炎、抗抑郁、抗糖尿病等多方面均表现出了比较明显的生物活性，且临床上使用的众多药物均含有酰胺基团。此外，以哌啶甲酸作为linker的酰胺类衍生物也具备较高的几丁质合成酶抑制活性，在抗癌等医学领域均表现出了优异的活性。这类化合物的研究文章可见：Analytical Biochemistry. 2002, 305(1): 97-105；Eur. J.Med. Chem. 2012,50:370-375；Bioorg. Med. Chem. Lett. 2014, 24(16): 3673-3682；Cheminform. 2006,37(20)；Bioorg. Med. Chem.2016, 24(23):6206-6214。以上文献均未覆盖或包括本发明所涉及的新型化合物的结构、合成方法和用途。
本发明设计并合成了一类1-氧代-2,8-二氮杂螺[4. 5]癸烷哌啶甲酸酰胺类化合物，以多抗霉素B、氟康唑、链霉素和左氧氟沙星为对照，测定了该类化合物在抗真菌、抗细菌方面的活性，拓展了此类化合物的应用范围。到目前为止，本发明所涉及的新型化合物在抗微生物活性方面还未见报道，所以可将其开发成新型的抗菌制剂。
发明内容
本发明的目的之一在于提供一种1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物；本发明的目的之二在于提供1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物的制备方法；本发明的目的之三在于提供所述的1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物在制备抗细菌/抗真菌药物中的应用。
为达到上述目的，本发明提供如下技术方案：
1、本发明所述的1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物结构如通式1所示：
其中R1为H，R2为2-CH3OC6H4，4-ClC6H4，3-CH3C6H4，2,4-FC6H3，3-BrC6H4，Ph，4-FC6H4，3-F3CC6H4，3-Cl-4-FC6H3，CHCH3C6H5，4-CH3OC6H4，2-FC6H4，3-O2NC6H4，3,5-CH3C6H3，4-BrC6H4，3-CH3OC6H4，2-CH3C6H4，3,4-FC6H3等，具体地，通式1所示的1-氧代-2, 8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物为下述化合物的任意一种：
上述1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物的合成方法，按如Scheme1所示进行：
具体地说，上述Scheme 1 反应条件如下：
a. 化合物2与氯乙酰氯经取代反应生成化合物4。溶剂为二氯甲烷、三氯甲烷、四氢呋喃等，优选二氯甲烷；化合物2与氯乙酰氯的摩尔比为1: 1.1~2，0℃至45℃反应8-12 h；
b. 化合物5与邻甲氧基苯胺经缩合反应，最后脱Boc生成化合物7a，溶剂为二氯甲烷、三氯甲烷、四氢呋喃等，优选二氯甲烷；化合物5与邻甲氧基苯胺的摩尔比1: 1.1~2，室温至45℃反应6-10 h；
c. 化合物4与化合物7a经取代反应生成化合物1, 溶剂为三氯甲烷、乙腈、DMF等，优选乙腈；化合物4与化合物7a的摩尔比为1: 1.1~2，室温至70℃反应4-8 h。
本领域普通技术人员均可按上述公开的制备方法制得相应的化合物。
上述1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物在制备抗病原微生物药物中的应用。所述微生物为病原细菌或病原真菌，如大肠杆菌、金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌、枯草杆菌、变形杆菌、铜绿色假单胞菌；白色念珠菌、新型隐球菌、黄曲霉菌、烟曲霉菌等。
具体实施方式
为了加深对本发明的理解，下面将结合实施例对本发明作进一步详述，该实施例仅用于解释本发明，并不构成对本发明保护范围的限定，但本领域的技术人员根据本发明的上述内容作出的一些非本质的改进和调整均属于本发明的保护范围。
所有使用的试剂都是商业购买的分析纯或化学纯，如未说明则未经过特殊处理。反应进度通过TLC跟踪监测，在紫外灯254 nm处显色，部分用碘和浓硫酸显色。熔点使用X-4显微熔点仪测定。核磁共振氢谱和碳谱使用Bruker Av-600型傅立叶变换核磁共振仪测定，使用的氘代试剂有CDCl3，DMSO-d6和MeOD，内含内标物质TMS。化学位移δ单位为ppm，偶合常数J单位为Hz，s、d、t、q、m分别表示单峰、两重峰、三重峰、四重峰和多重峰。HRMS(ESI)使用Bruker impactⅡ测定。
实施例1、8-（2-氯乙酰基）-2,8-二氮杂螺[4.5]癸-1-酮4的制备
在50 mL圆底烧瓶中加入化合物2（0.62 g，4.0mmol），无水碳酸钾（0.66 g，4.8 mmol），干燥的二氯甲烷（15 mL），室温下搅拌30min，冰浴滴加氯乙酰氯即化合物3（0.4 mL，4.8mmol）的二氯甲烷溶液（15mL）。室温下搅拌过夜，然后回流30 min，冷却至室温，加入5%的碳酸氢钠溶液（20 mL），搅拌10 min后用二氯甲烷萃取（25 mL×2），合并有机层，无水硫酸钠干燥，抽滤，真空浓缩，柱层析后即得化合物4（0.39 g），白色粉末，收率42.5%，熔点：149.7-151.1℃；1H NMR (600 MHz, CDCl3) δ 6.62 (s, 1H, CONH), 4.14-4.02 (m, 2H,CH2),4.01-3.81 (m, 2H, diazaspiro-CH2), 3.35-3.25 (m, 4H, diazaspiro-CH2), 2.05-1.96 (m, 2H, diazaspiro-CH2), 1.93-1.78 (m, 2H, diazaspiro-CH2), 1.51-1.43 (m,2H, diazaspiro-CH2).13C NMR (151 MHz, CDCl3) δ 180.12(1C), 164.08(1C), 42.14(1C), 40.58(1C), 39.99(1C), 37.95(1C), 37.76(1C), 31.95(1C), 31.87(1C), 30.87(1C). HRMS(ESI): calcd for C10H15ClN2O2[M+H]+, 231.0895, found, 231.0899。
实施例2、N-（2-甲氧基苯基）哌啶-4-甲酰胺（7a）的制备
在100 mL 圆底烧瓶中加入1-（叔丁氧基羰基）哌啶-4-羧酸即化合物5（2.35 g，10.2mmol），吡啶（2.1 mL，26.0mmol），二氯甲烷(30 mL)，充入氮气保护，在室温下加入氯化亚砜(0.9 mL， 12.4 mmol)，继续搅拌30 min，向其中缓慢滴加含有邻甲氧基苯胺（1.42 g，11.5mmol），三乙胺（4.9 mL，35.3mmol），催化量DMAP的二氯甲烷溶液（30mL），滴加完毕后室温反应10 h，依次用1mol/mL的盐酸（30 mL×2）、饱和碳酸氢钠（30 mL×2）洗涤，用无水硫酸钠干燥，抽滤，真空浓缩，柱层析后即得中间体（2.47 g），将中间体（2.47 g）加入（50mL）乙酸乙酯中，搅拌溶解后，加入15%的盐酸（2.5 mL），在50℃下反应8 h，冷却至室温，抽滤，得白色固体，将白色固体溶于10mL水中，用15%的氢氧化钠溶液调节PH至8-9，有白色固体析出，用乙酸乙酯萃取（30 mL×2），有机层用无水硫酸钠干燥，抽滤，真空浓缩即得化合物7a（1.40 g），白色粉末，产率80.9%，熔点：96.8-97.8℃；1H NMR (600 MHz, CDCl3) δ 8.32(d, J=7.6 Hz, 1H, CONH), 7.78 (s, 1H, Ar-H), 6.96 (t, J=7.3 Hz, 1H, Ar-H),6.88 (t, J=7.5 Hz, 1H, Ar-H), 6.80 (d, J=7.9 Hz, 1H, Ar-H), 3.81 (s, 3H, Ar-OCH3), 3.11 (d, J=11.9 Hz, 2H, piperidine-CH2), 2.61 (t, J=12.0 Hz, 2H,piperidine-CH2), 2.38-2.31 (m, 1H, piperidine-CH), 1.86 (d, J=12.3 Hz, 2H,piperidine-CH2), 1.74 (s, 1H, NH), 1.68-1.61 (m, 2H, piperidine-CH2).13C NMR(151 MHz, CDCl3)： δ 172.02(1C), 146.85(1C), 126.73(1C), 122.54(1C), 120.13(1C), 118.80(1C), 108.88(1C), 54.70(1C), 45.07(2C), 44.17(1C), 29.02(2C)。
按照实施例2相同的方法，可制得化合物7b-7r：
实施例3、N-（2-甲氧基苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1a）的制备
在25 mL的圆底烧瓶中加入化合物7a（0.42 g，1.8 mmol），研磨后的碳酸钾（0.25 g，1.8 mmol），催化量的KI（0.07 g，0.4 mmol），乙腈10 mL，室温搅拌30 min，加入化合物4（0.35 g，1.5mmol），加热到70℃反应8 h，过滤，真空浓缩，柱层析后即得化合物1a（0.25g），白色粉末，产率39.6%，熔点：136.3-137.5℃；1H NMR (600 MHz, CDCl3) δ 8.30 (d, J=7.9 Hz, 1H, CONH), 7.78 (s, 1H, Ar-H), 6.96 (t, J=7.7 Hz, 1H, Ar-H), 6.88 (t,J=7.7 Hz, 1H, Ar-H), 6.80 (d, J=8.1 Hz, 1H, Ar-H), 6.31 (s, 1H,CONH), 3.82(s, 3H,Ar-OCH3), 3.31-3.06 (m, 6H, diazaspiro-CH2), 2.90 (d, J=10.8 Hz, 2H,CH2), 2.20 (dd, J=16.1, 6.9 Hz, 1H, piperidine-CH), 2.12-1.97 (m, 4H,piperidine-CH2), 1.95-1.74 (m, 8H, diazaspiro-CH2, piperidine-CH2), 1.47-1.37(m, 2H, diazaspiro-CH2). 13C NMR (151 MHz, CDCl3) δ 180.10(1C), 171.93(1C),167.10(1C), 146.87(1C), 126.68(1C), 122.60(1C), 120.10 (1C), 118.81(1C),108.90(1C), 60.88(1C), 54.72(1C), 52.15(1C), 51.99(1C), 43.27 (1C), 41.40(1C), 40.70(1C), 37.66(1C), 37.53(1C), 32.15(1C), 31.74(1C), 31.15(1C), 28.08(1C), 27.96(1C). HRMS(ESI): calcd for C23H32N4O4[M+H]+, 429.2496, found,429.2497。
按照实施例3相同的方法，可制备如下化合物1b-1r：
N-（4-氯苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1b）
产率41.5%；白色粉末；熔点：253.2-254.6℃；1H NMR (600 MHz, CDCl3) δ 8.11 (s,1H, CONH), 7.46 (d, J=8.5 Hz, 2H, Ar-H), 7.17 (d, J=8.6 Hz, 2H, Ar-H), 6.33(s, 1H, CONH), 3.29 (t, J=6.8 Hz, 2H, diazaspiro-CH2), 3.24-3.03 (m, 4H,diazaspiro-CH2), 2.89 (d, J=9.1 Hz, 2H, CH2), 2.22-2.18 (m, 1H, piperidine-CH), 2.03 (ddd, J= 28.4, 22.2, 16.1 Hz, 6H, diazaspiro-CH2, piperidine-CH2),1.77 (dd, J=32.5, 18.8 Hz, 6H, piperidine-CH2), 1.41 (t, J=16.7 Hz, 2H,diazaspiro-CH2). 13C NMR (151 MHz, CDCl3) δ 179.99(1C), 172.51(1C), 167.05(1C),135.96(1C), 127.93(1C), 127.85(2C), 120.19(2C), 60.85(1C), 52.06(2C), 42.84(1C), 41.48(1C), 40.79(1C), 37.72(1C), 37.63(1C), 32.12(1C), 31.57(1C), 31.17(1C), 27.81(2C). HRMS(ESI): calcd for C22H29ClN4O3[M+H]+, 433.2001, found,433.2000。
（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）-N-（间甲苯基）哌啶-4-甲酰胺（1c）
产率43.6%；白色粉末；熔点：167.8-168.9℃；1H NMR (600 MHz, DMSO) δ 9.78 (s,1H, CONH), 7.60 (s, 1H, Ar-H), 7.45 (s, 1H, Ar-H), 7.37 (d, J=8.1 Hz, 1H, Ar-H), 7.15 (t, J=7.8 Hz, 1H, Ar-H), 6.84 (d, J=7.5 Hz, 1H, CONH), 3.35 (s, 2H,diazaspiro-CH2), 3.25-3.04 (m, 6H, diazaspiro-CH2), 2.89-2.84 (m, 2H, CH2),2.33-2.25 (m, 4H, diazaspiro-CH2, piperidine-CH2), 2.00 (dd, J=6.6, 4.0 Hz,4H, piperidine-CH), 1.77-1.47 (m, 6H, piperidine-CH2), 1.37 (dd, J=32.8, 13.5Hz, 2H, diazaspiro-CH2).13C NMR (151 MHz, DMSO) δ 180.19(1C), 173.89(1C),167.84(1C), 139.75 (1C), 138.20(1C), 128.88(1C), 124.12(1C), 120.21(1C),116.83(1C), 61.80(1C), 53.08 (1C), 52.89(1C), 42.97(1C), 42.62(1C), 42.18(1C), 38.50(1C), 38.38(1C), 32.89(1C), 32.05(1C), 31.60(1C), 29.01(2C), 21.64(1C). HRMS(ESI): calcd for C23H32N4O3[M+H]+, 413.2547, found,413.2547。
（2,4-二氟苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1d）
产率38.8%；白色粉末；熔点：155.6-156.7℃；1H NMR (600 MHz, MeOD) δ 7.74 (dd,J=14.9, 8.8 Hz, 1H,Ar-H), 7.03 (dd, J=13.9, 5.5 Hz, 1H, Ar-H), 6.94 (t, J=8.5 Hz, 1H, Ar-H), 3.49 (dd, J=13.2, 5.1 Hz, 2H, diazaspiro-CH2), 3.23-3.07(m, 4H, diazaspiro-CH2), 2.81 (ddd, J=15.0, 12.0, 5.9 Hz, 2H,CH2), 2.15 (t, J=6.9 Hz, 1H, piperidine-CH), 2.05-1.93 (m, 6H, diazaspiro-CH2, piperidine-CH2),1.82-1.56 (m, 6H, piperidine-CH2), 1.40-1.22 (m, 2H, diazaspiro-CH2). 13C NMR(151 MHz, MeOD) δ 182.12(1C), 180.53(1C), 174.63(1C), 126.32(1C), 121.90(1C),110.56(1C), 103.64 (1C), 103.48(1C), 103.31(1C), 59.46(1C), 49.83(1C), 49.71(1C), 48.48(1C), 44.75 (1C), 42.34(1C), 41.26(1C), 40.60(1C), 38.36(1C),31.96(1C), 31.02(1C), 28.95(1C), 28.13(1C). HRMS(ESI): calcd for C22H28F2N4O3[M+H]+, 435.2202, found, 435.2209。
（3-溴苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1e）
产率40.7%；白色粉末；熔点：180.3-181.6℃；1H NMR (600 MHz, CDCl3) δ 8.74 (s,1H, CONH), 7.74 (s, 1H, Ar-H), 7.46 (d, J=8.1 Hz, 1H, Ar-H), 7.12 (d, J=8.0Hz, 1H,Ar-H), 7.07 (t, J=8.0 Hz, 1H, Ar-H), 6.29 (s, 1H, CONH), 3.28-2.96 (m,6H, diazaspiro-CH2), 2.74 (t, J=11.9 Hz, 2H, CH2), 2.54-2.48 (m, 1H,piperidine-CH), 2.13 -1.91 (m, 4H, piperidine-CH2), 1.89-1.58 (m, 8H,diazaspiro-CH2, piperidine-CH2), 1.36 (t, J=12.9 Hz, 2H, diazaspiro-CH2). 13CNMR (151 MHz, CDCl3) δ 181.01(1C), 172.09(1C), 167.25(1C), 138.86(1C), 129.21(1C), 125.88(1C), 121.86(1C), 121.40 (1C), 117.48(1C), 61.30(1C), 48.99(1C),48.76(1C), 44.23(1C), 42.39(1C), 40.76(1C), 40.39(1C), 37.78(1C), 31.20(2C),30.44(1C), 28.23(1C), 27.52(1C). HRMS(ESI): calcd for C22H29BrN4O3 [M+Na]+,499.1315, found, 499.1314。
（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）乙基）-N-苯基哌啶-4-甲酰胺（1f）
产率43.3%；白色粉末；熔点：246.7-247.6℃；1H NMR (600 MHz, DMSO) δ 9.84 (s,1H, CONH), 7.61-7.57 (m, 3H, Ar-H), 7.28 (t, J=7.9 Hz, 2H, Ar-H), 7.02 (t, J=7.3 Hz, 1H, CONH), 3.15 (ddd, J=54.2, 29.4, 11.2 Hz, 6H, diazaspiro-CH2),2.87 (d, J=11.0 Hz, 2H, CH2), 2.31 (ddd, J=15.3, 7.8, 3.6 Hz, 1H, piperidine-CH), 2.05-1.99 (m, 4H, piperidine-CH2), 1.83-1.41 (m, 8H, diazaspiro-CH2,piperidine-CH2), 1.40-1.32 (m, 2H, diazaspiro-CH2).13C NMR (151 MHz, DMSO) δ180.18(1C), 173.93(1C), 167.84 (1C), 139.85(1C), 129.05(2C), 123.42(1C),119.62(2C), 61.83(1C), 53.09(1C), 52.90 (1C), 43.02(1C), 42.62(1C), 42.17(1C), 38.50(1C), 38.38(1C), 32.92(1C), 32.06(1C), 31.62(1C), 29.02(2C). HRMS(ESI): calcd for C22H30N4O3[M+H]+, 399.2391, found,399.2383。
（4-氟苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1g）
产率37.6%；白色粉末；熔点：164.8-165.7℃；1H NMR (600 MHz, DMSO) δ 9.98 (s,1H, CONH), 7.62 (dd, J=8.9, 5.0 Hz, 2H, Ar-H), 7.53 (s, 1H, CONH), 7.12 (t, J=8.9 Hz, 2H, Ar-H), 3.09 (dt, J=24.0, 9.3 Hz, 4H, diazaspiro-CH2), 2.77 (s,2H, CH2), 2.59 (ddd, J=16.8, 11.6, 8.2 Hz, 3H, diazaspiro-CH2, piperidine-CH),2.12 (s, 2H, piperidine-CH2), 1.90 (d, J=6.8 Hz, 2H, piperidine-CH2), 1.86-1.39 (m, 8H, diazaspiro-CH2, piperidine-CH2), 1.37-1.30 (m, 2H, diazaspiro-CH2). 13C NMR (151 MHz, DMSO) δ 180.68(1C), 173.30(1C), 159.16(1C), 157.58(1C), 136.12(1C), 121.42(2C), 115.69 (1C), 115.54(1C), 61.67(1C), 50.04(1C),49.79(1C), 45.17(1C), 43.00(1C), 41.55(1C), 41.22(1C), 38.32(1C), 32.03(2C),31.30(1C), 29.43(1C), 28.74(1C). HRMS(ESI): calcd for C22H29FN4O3[M+H]+,417.2296, found, 417.2303。
（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）乙基）-N-（3-（三氟甲基）苯基）哌啶-4-甲酰胺（1h）
产率45.7%；白色粉末；熔点：132.8-134.6℃；1H NMR (600 MHz, CDCl3) δ 8.92 (s,1H, CONH), 7.79 (d, J=8.9 Hz, 2H, Ar-H), 7.33 (t, J=7.8 Hz, 1H, Ar-H), 7.24(d, J=7.7 Hz, 1H, Ar-H), 6.21 (s, 1H, CONH), 3.26-.01 (m, 5H, diazaspiro-CH2), 2.79 -2.67 (m, 3H, CH2, diazaspiro-CH2), 2.56 (ddd, J=14.6, 10.8, 3.7Hz, 1H, piperidine-CH), 2.10 (dd, J=27.5, 12.1 Hz, 2H, piperidine-CH2), 1.94(dd, J=12.6, 6.4 Hz, 2H, piperidine-CH2), 1.92-1.48 (m, 8H, diazaspiro-CH2,piperidine-CH2), 1.36 (t, J=13.5 Hz, 2H, diazaspiro-CH2). 13C NMR (151 MHz,CDCl3) δ 180.96(1C), 172.23(1C), 167.24(1C), 138.13(1C), 130.12(1C), 128.42(1C), 122.04(1C), 119.40(1C), 115.60 (1C), 61.28(1C), 48.98(1C), 48.76(1C),44.22(1C), 42.38(1C), 40.72(1C), 40.38(1C), 37.74(1C), 31.20(2C), 30.43(1C),29.67(1C), 28.23(1C), 27.49(1C).HRMS(ESI): calcd for C23H29F3N4O3[M+H]+,467.2265, found, 467.2270。
（3-氯-4-氟苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1i）
产率49.0%；白色粉末；熔点：173.2-174.8℃；1H NMR (600 MHz, CDCl3) δ 8.66 (s,1H, CONH), 7.68 (dd, J=6.5, 2.4 Hz, 1H, Ar-H), 7.39-7.35 (m, 1H, Ar-H), 6.98(t, J=8.8 Hz, 1H, Ar-H), 6.12 (s, 1H, CONH), 3.26 (t, J=6.9 Hz, 2H,diazaspiro-CH2), 3.15-2.99 (m, 3H, diazaspiro-CH2), 2.71 (dt, J=37.2, 11.4 Hz,3H, CH2, diazaspiro-CH2), 2.50 (ddd, J=14.6, 10.8, 3.7 Hz, 1H, piperidine-CH),2.21-2.05 (m, 4H, piperidine-CH2), 1.97-1.63 (m, 8H, diazaspiro-CH2, piperidine-CH2), 1.37 (t, J=12.3 Hz, 2H, diazaspiro-CH2). HRMS(ESI): calcd forC22H28ClFN4O3[M+H]+, 451.1907, found, 451.1909。
（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）-N-（1-苯乙基）哌啶-4-甲酰胺（1j）
产率44.5%；白色粉末；熔点：106.9-108.5℃；1H NMR (600 MHz, CDCl3) δ 7.23 (d,J=9.2 Hz, 4H, Ar-H), 7.16 (t, J=6.4 Hz, 1H, Ar-H), 6.51 (d, J=7.1 Hz, 1H,CONH), 5.02 (p, J=7.0 Hz, 1H, CH), 3.35-2.90 (m, 6H, diazaspiro-CH2), 2.72(s, 2H, CH2), 2.57 (q, J=11.8 Hz, 1H, piperidine-CH), 2.09 (dd, J=21.8, 10.8Hz, 2H, piperidine-CH2), 2.02-1.42 (m, 10H, diazaspiro-CH2, piperidine-CH2),1.39 (dd, J=6.8, 2.6 Hz, 3H,CH3), 1.33 (d, J=8.7 Hz, 2H, diazaspiro-CH2 ). 13CNMR (151 MHz, CDCl3) δ 181.09(1C), 172.35(1C), 167.13(1C), 142.51(1C), 127.61(2C), 126.20(1C), 125.14 (2C), 61.20(1C), 48.86(2C), 47.52(1C), 44.23(1C),41.74(1C), 40.78(1C), 40.43(1C), 37.78(1C), 31.15(2C), 30.49(1C), 28.36(1C),27.59(1C), 20.83(1C). HRMS(ESI): calcd for C24H34N4O3[M+Na]+, 449.2523, found,449.2523。
（4-甲氧基苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1k）
产率48.2%；白色粉末；熔点：217.6-218.9℃；1H NMR (600 MHz, CDCl3) δ 7.62 (s,1H, CONH), 7.37 (d, J=8.9 Hz, 2H, Ar-H), 6.76 (d, J=8.9 Hz, 2H, Ar-H), 6.18(s, 1H, CONH), 3.71 (s, 3H, Ar-OCH3), 3.30-3.03 (m, 6H, diazaspiro-CH2), 2.88(s, 2H, CH2), 2.19-2.13 (m, 1H, piperidine-CH), 2.09-1.98 (m, 6H, diazaspiro-CH2, piperidine-CH2), 1.86-1.73 (m, 6H, diazaspiro-CH2, piperidine-CH2), 1.45-1.37(m, 2H, diazaspiro-CH2). 13C NMR (151 MHz, CDCl3) δ 179.96(1C), 172.07(1C), 167.09(1C), 155.39 (1C), 130.24(1C), 120.79(2C), 113.15(2C), 60.87(1C),54.51(1C), 52.08(2C), 42.80 (1C), 41.46(1C), 40.67(1C), 37.61(2C), 32.16(1C),31.72(1C), 31.18(1C), 27.94(2C). HRMS(ESI): calcd for C23H32N4O4[M+H]+,429.2496, found,429.2500。
（2-氟苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1l）
产率39.6%；白色粉末；熔点：151.4-152.7℃；1H NMR (600 MHz, DMSO) δ 9.68 (s,1H, CONH), 7.86 (t, J=8.6 Hz, 1H, Ar-H), 7.51 (s, 1H, CONH), 7.29-7.21 (m,1H, Ar-H), 7.14 (dd, J=4.9, 2.4 Hz, 2H, Ar-H), 3.34-3.13 (m, 6H, diazaspiro-CH2), 3.03 (t, J=11.6 Hz, 2H, piperidine-CH2), 2.75 (dd, J=12.1, 9.1 Hz, 2H,CH2), 2.63 (t, J= 12.1 Hz, 1H, piperidine-CH), 2.08 (d, J=8.5 Hz, 2H,piperidine-CH2), 1.87 (dt, J=32.1, 11.9 Hz, 4H, diazaspiro-CH2), 1.72-1.43 (m,4H, piperidine-CH2), 1.32 (d, J=9.3 Hz, 2H, diazaspiro-CH2). 13C NMR (151 MHz,DMSO) δ 180.75(1C), 173.85(1C), 167.84(1C), 155.15(1C), 126.68(1C), 125.74(1C), 125.00(1C), 124.69(1C), 115.93(1C), 61.92(1C), 50.04(1C), 49.76(1C),45.22(1C), 42.42(1C), 41.64(1C), 41.21(1C), 38.33(1C), 32.17 (2C), 31.26(1C),29.52(1C), 28.84(1C). HRMS(ESI): calcd for C22H29FN4O3[M+Na]+, 439.2116, found,439. 2119。
（3-硝基苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1m）
产率39.8%；白色粉末；熔点：118.5-119.7℃；1H NMR (600 MHz, DMSO) δ 10.82 (s,1H, CONH), 8.01 (d, J=8.2 Hz, 1H, Ar-H), 7.87 (dd, J=8.2, 1.5 Hz, 1H, Ar-H),7.71 (s, 1H, Ar-H), 7.60 (d, J=8.2 Hz, 1H, Ar-H), 6.73 (s, 1H, CONH), 3.26(dt, J=12.5, 4.4 Hz, 2H, diazaspiro-CH2), 3.18-3.13 (m, 4H, diazaspiro-CH2 ),2.97-2.92 (m, 2H, CH2), 2.01-1.78 (m, 4H, piperidine-CH2), 1.59-1.49 (m, 8H,diazaspiro-CH2, piperidine-CH2), 1.30 (dd, J=13.8, 6.3 Hz, 2H, diazaspiro-CH2).13C NMR (151 MHz, DMSO) δ 179.38(1C), 174.26(1C), 170.84(1C), 148.38(1C),130.48(1C), 125.62(1C), 123.10(1C), 118.00(1C), 113.68(1C), 63.94(1C), 49.01(1C), 49.76(1C), 44.22(1C), 42.62(1C), 41.84(1C), 40.16(1C), 38.34(1C), 31.99(2C), 30.63(1C), 29.91(1C), 28.93 (1C).HRMS(ESI): calcd for C22H29N5O5[M+H]+,444.2241, found, 444.2242。
（3,5-二甲基苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1n）
产率51.3%；白色粉末；熔点：148.6-149.7℃；1H NMR (600 MHz, CDCl3) δ 7.83 (s,1H, CONH), 7.11 (s, 2H, Ar-H), 6.66 (s, 1H, Ar-H), 6.15 (s, 1H, CONH), 3.24(t, J=6.9 Hz, 2H, diazaspiro-CH2), 3.13 (s, 2H, diazaspiro-CH2), 2.75 (t, J=11.0 Hz, 2H, CH2), 2.44 (t, J=10.9 Hz, 1H, piperidine-CH), 2.20 (s, 6H, Ar-CH3), 2.16-2.09 (m, 6H, diazaspiro-CH2, piperidine-CH2), 1.96-1.84 (m, 6H,diazaspiro-CH2, piperidine-CH2 ), 1.68 (dd, J=44.9, 10.0 Hz, 2H, piperidine-CH2), 1.36 (dd, J=20.5, 8.5 Hz, 2H, diazaspiro-CH2). 13C NMR (151 MHz, CDCl3) δ180.98(1C), 171.59(1C), 167.20(1C), 137.61(2C), 136.89(1C), 124.99(1C),116.81(2C), 61.16(1C), 48.91(1C), 48.78(1C), 44.21(1C), 42.69(1C), 40.67(1C),40.39(1C), 37.71(1C), 31.19(2C), 30.55(1C), 28.32(1C), 27.64(1C), 20.35(2C).HRMS(ESI): calcd for C24H34N4O3[M+H]+, 427.2704, found, 427. 2712。
（4-溴苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1o）
产率35.5%；白色粉末；熔点：164.8-166.2℃；1H NMR (600 MHz, DMSO) δ 10.07 (s,1H, CONH), 7.59 (d, J=8.9 Hz, 2H, Ar-H), 7.47 (d, J=8.8 Hz, 2H, Ar-H), 7.12(s, 1H, CONH), 3.15 (t, J=6.8 Hz, 2H, diazaspiro-CH2), 3.03 (t, J=12.0 Hz,2H, diazaspiro-CH2), 2.76-2.71 (m, 2H, CH2), 2.65-2.58 (m, 2H, diazaspiro-CH2), 2.52-2.50 (m, 1H, piperidine-CH), 2.11-2.05 (m, 2H, piperidine-CH2),1.90 (d, J=6.8 Hz, 2H, piperidine-CH2), 1.85-1.44 (m, 8H, diazaspiro-CH2,piperidine-CH2), 1.33 (dd, J=10.5, 4.9 Hz, 2H, diazaspiro-CH2). 13C NMR (151MHz, DMSO) δ 180.75(1C), 173.60(1C), 167.84(1C), 139.12(1C), 131.89(2C),121.62(2C), 115.59(1C), 61.87(1C), 50.03(1C), 49.77(1C), 45.20(1C), 43.12(1C), 41.63(1C), 41.18(1C), 38.33(1C), 32.18(2C), 31.28 (1C), 29.41(1C),28.71(1C).HRMS(ESI): calcd for C22H29BrN4O3[M+H]+, 477.1496, found,477. 1487。
（3-甲氧基苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1p）
产率45.6%；白色粉末；熔点：109.8-111.0℃；1H NMR (600 MHz, DMSO) δ 10.00 (s,1H, CONH), 7.59 (s, 1H, Ar-H), 7.35 (s, 1H, Ar-H), 7.21-7.14 (m, 2H, Ar-H),6.61 (d, J=6.6 Hz, 1H, CONH), 3.72 (s, 3H, Ar-OCH3), 3.30 (d, J=12.7 Hz, 2H,diazaspiro-CH2), 3.18 (t, J=9.8 Hz, 4H, diazaspiro-CH2), 3.07-2.96 (m, 2H,piperidine-CH2), 2.65 (t, J=11.1 Hz, 2H, CH2), 1.92 (d, J=4.9 Hz, 2H,piperidine-CH2), 1.71 (ddd, J=43.1, 28.0, 12.6 Hz, 8H, diazaspiro-CH2, piperidine-CH2), 1.43 (s, 2H, diazaspiro-CH2). 13C NMR (151 MHz, DMSO) δ180.36(1C), 179.35(1C), 173.45(1C), 159.94 (1C), 140.94(1C), 129.82(1C),111.96(1C), 109.11(1C), 105.46(1C), 63.95(1C), 55.45 (1C), 50.04(1C), 49.84(1C), 44.99(1C), 42.95(1C), 41.28(1C), 38.33(1C), 31.90(1C), 31.44(2C), 29.31(1C), 29.00(1C), 28.67(1C).HRMS(ESI): calcd for C23H32N4O4[M+H]+, 429.2496,found,429.2493。
（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）-N-（邻甲苯基）哌啶-4-甲酰胺（1q）
产率42.8%；白色粉末；熔点：121.9-123.2℃；1H NMR (600 MHz, MeOD) δ 7.28 (d, J=7.6 Hz, 1H, Ar-H), 7.22 (d, J=7.3 Hz, 1H, Ar-H), 7.18-7.11 (m, 2H, Ar-H),3.24 (dt, J=23.4, 9.3 Hz, 4H, diazaspiro-CH2), 2.95 (d, J=7.2 Hz, 2H,diazaspiro-CH2), 2.77 (ddd, J=15.3, 12.9, 5.6 Hz, 2H, CH2), 2.35 (t, J=10.4Hz, 2H, piperidine-CH2), 2.23 (s, 3H, Ar-H), 2.06 (dd, J=7.4, 6.2 Hz, 2H,piperidine-CH2), 2.01-1.58 (m, 8H, diazaspiro-CH2, piperidine-CH2), 1.50 (d, J=11.1 Hz, 2H, diazaspiro-CH2). 13C NMR (151 MHz, MeOD) δ 182.32(1C), 174.56(1C), 168.09(1C), 135.42(1C), 133.20(1C), 130.21(1C), 126.14(1C), 125.93(1C),125.85(1C), 60.24(1C), 49.74(1C), 49.63(1C), 44.99(1C), 42.52(1C), 41.86(1C),41.30(1C), 38.44(1C), 31.42(2C), 31.09(1C), 29.20 (1C), 28.33(1C), 16.78(1C).HRMS(ESI): calcd for C23H32N4O[M+H]+, 413.2547, found, 413.2547。.
N-（3,4-二氟苯基）-1-（2-氧代-2-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）乙基）哌啶-4-甲酰胺（1r）
产率52.2%；白色粉末；熔点：203.7-205.1℃；1H NMR (600 MHz, CDCl3) δ 8.69 (s,1H, CONH), 7.57 (ddd, J=12.0, 7.2, 2.1 Hz, 1H, Ar-H), 7.15 (d, J=8.8 Hz, 1H,Ar-H), 6.99 (q, J=9.1 Hz, 1H, Ar-H), 6.19 (s, 1H, CONH), 3.35-2.94 (m, 6H,diazaspiro-CH2), 2.76 (dd, J=21.6, 10.0 Hz, 2H, CH2), 2.49 (td, J=10.9, 5.4Hz, 1H, piperidine-CH), 2.30-1.91 (m, 6H, diazaspiro-CH2, piperidine-CH2),1.87-1.63 (m, 6H, diazaspiro-CH2, piperidine-CH2), 1.37 (t, J=12.3 Hz, 2H,diazaspiro-CH2). 13C NMR (151 MHz, CDCl3) δ 180.99(1C), 171.90(1C), 167.26(1C), 148.97(1C), 145.73(1C), 134.03(1C), 116.02(1C), 114.59(1C), 108.63(1C),61.29(1C), 48.88(2C), 44.23(1C), 42.39(1C), 40.74(1C), 40.39(1C), 37.75(1C),31.22(2C), 30.42(1C), 28.23(1C), 27.50 (1C).HRMS(ESI): calcd for C21H28N4O3[M+H]+, 435.2202, found, 435.2200。
实施例4、1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物的几丁质合成酶活性抑制实验
从热带酵母细胞膜中提取的几丁质合成酶与底物UDP-GlcNAc在微孔板上发生孵化反应，产生的几丁质与微孔板上包被的WGA结合在一起，然后加入WGA-HRP与固定在板上的几丁质结合，将多余的试剂洗掉，然后使用TMB底物溶液检测HRP的活性，用2 M的硫酸终止反应，用ELISA检测仪在450 nm处检测其OD值，进而计算出抑制率和IC50值。
实施例3制得的化合物1a-1r都进行了几丁质合成酶抑制活性初筛，初筛的最高药物浓度为300 μg/mL，抑制率（IP, inhibition percentage）为该最高药物浓度对几丁质合成酶的抑制率，对几丁质合成酶抑制活性较好的化合物进一步测试其IC50值，结果如表1所示：
。
实施例5、1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物的体外抗微生物活性
采用符合美国国家委员会制定的临床实验标准（Clinical and LaboratoryStandards Institute, CLSI）的96孔微量稀释法，检查实施例3制得的1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物对革兰氏阳性菌（耐甲氧西林金黄色葡萄球菌（MRSA N315）、金黄色葡萄球菌（ATCC 25923）、枯草杆菌（ATCC 6633））、革兰氏阴性菌（大肠杆菌（JM109）、铜绿假单胞菌（ATCC 9027）、变形杆菌（ATCC 8427））和真菌（白色念珠菌（ATCC76615）、烟曲霉菌（GIMCC 3.19）、白色念珠菌（ATCC 90023）、黄曲霉菌（ATCC 16870）、新型隐球菌（ATCC 32719））的最低抑制浓度（MIC），将待测化合物用少量二甲亚砜溶解，用灭菌水配制成溶液备用，将96孔板，枪头等进行紫外灭菌，取稀释好的菌液100uL加入到96孔板中，用链霉素，左氧氟沙星；氟康唑和多抗霉素 B作为参比对照。细菌，真菌在37℃培养18~24h，观察现象，结果见表2~3：
由表可以看出，本发明制得的化合物1a-1r，对所测试的细菌和真菌均表现出一定的抑制作用，特别地， 1h分别对白色念珠菌（ATCC 76615）、烟曲霉菌、白色念珠菌（ATCC9002300）、新型隐球菌表现出较高的抗菌活性，MIC值都为16 µg/mL。部分化合物抗真菌活性与参考药物氟康唑相接近。
Claims (8)
1.1-氧代-2,8-二氮杂螺[4.5]癸烷哌啶甲酸酰胺类化合物及其制备方法和应用，其特征在于：该螺环化合物8-位通过4-哌啶甲酸酰胺与一含氮的片断相连，组成如通式1所示结构的化合物：
。
2.如权利要求1所述，该类化合物中取代基为可为以基团：
其中R1为H；R2为2-CH3OC6H4，4-ClC6H4，3-CH3C6H4，2,4-FC6H3，3-BrC6H4，Ph，4-FC6H4，3-F3CC6H4，3-Cl-4-FC6H3，CHCH3C6H5，4-CH3OC6H4，2-FC6H4，3-O2NC6H4，3,5-CH3C6H3，4-BrC6H4，3-CH3OC6H4，2-CH3C6H4，3,4-FC6H3等。
3.如权利要求1所述化合物的合成方法，按Scheme1所示合成路线进行
。
4.如权利要求3所示，步骤(a)中，溶剂为二氯甲烷、三氯甲烷、四氢呋喃等，优选二氯甲烷；化合物2与氯乙酰氯的摩尔比为1: 1.1~2，0℃至45℃反应8-12 h。
5.如权利要求3所示，步骤(b)中，溶剂为二氯甲烷、三氯甲烷、四氢呋喃等，优选二氯甲烷；化合物5与邻甲氧基苯胺的摩尔比1: 1.1~2，室温至45℃反应6-10 h。
6.如权利要求3所示，步骤(c)中，溶剂为三氯甲烷、乙腈、DMF等，优选乙腈；化合物4与化合物7a的摩尔比为1: 1.1~2，室温至70℃反应4-8 h。
7.如权利要求2所述化合物在制备抗病原微生物药物中的应用，所述微生物为病原细菌或病原真菌，如大肠杆菌、金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌、枯草杆菌、变形杆菌、铜绿色假单胞菌；白色念珠菌、新型隐球菌、黄曲霉菌、烟曲霉菌等。
8.如权利要求2所述化合物在几丁质合成酶抑制剂药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910070042.5A CN109593089B (zh) | 2019-01-24 | 2019-01-24 | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910070042.5A CN109593089B (zh) | 2019-01-24 | 2019-01-24 | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109593089A true CN109593089A (zh) | 2019-04-09 |
| CN109593089B CN109593089B (zh) | 2022-01-28 |
Family
ID=65966693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910070042.5A Expired - Fee Related CN109593089B (zh) | 2019-01-24 | 2019-01-24 | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109593089B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021042911A1 (zh) * | 2019-09-05 | 2021-03-11 | 鲁南制药集团股份有限公司 | Magl抑制剂及其制备方法、用途 |
| CN116143782A (zh) * | 2021-11-22 | 2023-05-23 | 西南大学 | 一类螺[吡咯烷-2,3’-喹啉]-2‘-酮类衍生物的设计合成与应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004055011A1 (en) * | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Heterocyclic compounds as ccr5 antagonists |
| WO2004055012A1 (en) * | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Indane compounds as ccr5 antagonists |
| CN1802375A (zh) * | 2003-04-09 | 2006-07-12 | 千禧药品公司 | 用于治疗炎性疾病的β－咔啉 |
-
2019
- 2019-01-24 CN CN201910070042.5A patent/CN109593089B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004055011A1 (en) * | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Heterocyclic compounds as ccr5 antagonists |
| WO2004055012A1 (en) * | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Indane compounds as ccr5 antagonists |
| CN1802375A (zh) * | 2003-04-09 | 2006-07-12 | 千禧药品公司 | 用于治疗炎性疾病的β－咔啉 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021042911A1 (zh) * | 2019-09-05 | 2021-03-11 | 鲁南制药集团股份有限公司 | Magl抑制剂及其制备方法、用途 |
| CN116143782A (zh) * | 2021-11-22 | 2023-05-23 | 西南大学 | 一类螺[吡咯烷-2,3’-喹啉]-2‘-酮类衍生物的设计合成与应用 |
| CN116143782B (zh) * | 2021-11-22 | 2024-04-12 | 西南大学 | 一类螺[吡咯烷-2,3'-喹啉]-2'-酮类衍生物的设计合成与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109593089B (zh) | 2022-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109593089A (zh) | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 | |
| US20110086817A1 (en) | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria | |
| Tang et al. | Synthesis and characterization of thiophene‐derived amido bis‐nitrogen mustard and its antimicrobial and anticancer activities | |
| Kudryavtseva et al. | Synthesis and antimicrobial activity of acridine carboxylic acid derivatives containing a piperazine moiety | |
| JPS604820B2 (ja) | キノリンカルボン酸誘導体 | |
| CN113264949B (zh) | 一类螺苯并噁嗪哌啶α,β-不饱和酮类衍生物的设计合成与应用 | |
| Ali et al. | Synthesis, Characterization and Antibacterial Evaluation of Oxoazetidin—Benzene Sulfonamide Derivatives as a Hybrid Antimicrobial Agents | |
| CN110713459A (zh) | 一类喹啉酮富马来酰胺衍生物的设计合成与应用 | |
| DE60309349T2 (de) | Propanamine derivate als serotonin und norepinephrin reuptake-inhibitoren | |
| RamaGanesh et al. | Synthesis and biological evaluation of some innovative coumarin derivatives containing thiazolidin-4-one ring | |
| Abbaz et al. | Synthesis, characterization and antibacterial activity of cyclic sulfamide linked to tetrathiafulvalene (TTF) | |
| CN110526910A (zh) | 一种噻唑橙苄基类季铵盐衍生物及其制备方法和应用 | |
| Mehrabani et al. | Thiazolidine-2-thione and 2-imino-1, 3-dithiolane derivatives: synthesis and evaluation of antimicrobial activity | |
| CN109400608A (zh) | 二氮杂螺[4，5]癸烷酒石酸类衍生物制备和应用 | |
| FR2645862A1 (fr) | Derives d'isothiazolo-pyrydone azetidinyl substitues, leur preparation et leur application en tant que medicaments | |
| Datta et al. | Synthesis of some new 4-thiazolidinones as biologically potent agents | |
| Tandel et al. | Synthesis and antibacterial activity of novel coumarin–chalcone hybrids | |
| ULUSOY et al. | Synthesis and antimicrobial activity of novel imidazo [2, 1-b] thiazolyl acetyl amino/hydrazono 4-thiazolidinones | |
| Abdel-Hafez et al. | Synthesis of selenium-containing amino acid analogues and their biological study | |
| Shahare et al. | Antimicrobial evaluation of some novel aldimine derivatives | |
| Patel et al. | Synthesis, Characterization And Antimicrobial Screening Of Sulfadiazine-2-Azetidinone-1, 2, 4-Triazole Clubbed Derivatives | |
| CN116143782B (zh) | 一类螺[吡咯烷-2,3'-喹啉]-2'-酮类衍生物的设计合成与应用 | |
| IJEOMAH et al. | SYNTHESIS, CHARACTERISATION AND ANTIBACTERIAL ACTIVITY OF 2-(PHENYL SULFONYL) AMINO PYRIDINE. | |
| Singh et al. | Synthesis of some new 1, 3-thiazolyldiphenyl amine derivative and evaluation of their antibacterial effects | |
| Vasoya et al. | Green chemistry approach to the synthesis of potentially bioactive aminobenzylated Mannich bases through active hydrogen compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220128 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |